21 - 25 out of 25Page size: 10
  1. 2018

  2. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME (R) trial

    EMPA-REG OUTCOME Investigators, 1 Feb 2018, In: European Heart Journal. 39, 5, p. 363-370 8 p.

    Research output: Contribution to journal › Article › peer-review

  3. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

    EMPA-REG OUTCOME Investigators, 9 Jan 2018, In: Circulation. 137, 2, p. 119-129 11 p.

    Research output: Contribution to journal › Article › peer-review

  4. 2017

  5. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

    EMPA-REG OUTCOME Investigators, May 2017, In: Stroke. 48, 5, p. 1218-+ 31 p.

    Research output: Contribution to journal › Article › peer-review

  6. 2016

  7. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

    EMPA-REG OUTCOME Investigators, 14 May 2016, In: European Heart Journal. 37, 19, p. 1526-1534 9 p.

    Research output: Contribution to journal › Article › peer-review

  8. 2002

  9. Izmeneniia tsentral'noĭ gemodinamiki u bol'nykh s limfomami

    Shevchenko, YL., Bobrov, LL., Novik, AA., Obrezan, AG. & Krysyuk, OB., 2002, In: Terapevticheskii Arkhiv. 74, 10, p. 72-74 3 p.

    Research output: Contribution to journal › Article › peer-review

Previous 1 2 3 Next

ID: 19152169